Guardant Health宣布第四季度初步销售额约为2亿美元,同比增长29%,超过预期的1.8673亿美元

财报速递
13 Jan

2024年第四季度初步未经审计的财务结果

  • 总收入约为2亿美元,同比增长29%
  • 报告约57,300次肿瘤临床测试(不包括Shield)和约11,050次生物制药测试,分别增长24%和16%
  • 报告约6,400次Shield筛查测试,收入约400万美元


以上内容来自Benzinga Earnings专栏,原文如下:

Fourth quarter 2024 preliminary unaudited financial results

  • Total revenue of approximately $200 million, an increase of 29%
  • Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increase of 24% and 16%, respectively
  • Reported approximately 6,400 Shield screening tests, with revenue of approximately $4 million

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10